Abstract
The purpose of this review is to examine sex differences in response to stimulation and inhibition of the renin-angiotensin system (RAS). The RAS plays a prominent role in the development of chronic renal disease, and there are known sex differences not only in the expression level of components of the RAS but also in how males and females respond to perturbations of the RAS. In men, renal injury increases in parallel with increased activation of the RAS, while in women, increases in ANG II do not necessarily translate into increases in renal injury. Moreover, both epidemiological and experimental studies have noted sex differences in the therapeutic benefits following angiotensin-converting enzyme inhibitor and angiotensin receptor blocker treatment. Despite these differences, RAS inhibitors are the most commonly prescribed drugs for the treatment of chronic renal disease, irrespective of sex. This review will examine how males and females respond to stimulation and inhibition of the RAS, with a focus on renal disease.
| Original language | English (US) |
|---|---|
| Journal | American Journal of Physiology - Regulatory Integrative and Comparative Physiology |
| Volume | 294 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 1 2008 |
Fingerprint
Keywords
- Angiotensin receptor blocker
- Angiotensin-converting enzyme inhibitors
- Janus kinase/signal transducers and activators of transcription
- Nuclear factor-κβ
- Transforming growth factor-β
ASJC Scopus subject areas
- Physiology
Cite this
Sex and the renin-angiotensin system : Inequality between the sexes in response to RAS stimulation and inhibition. / Sullivan, Jennifer C.
In: American Journal of Physiology - Regulatory Integrative and Comparative Physiology, Vol. 294, No. 4, 01.04.2008.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Sex and the renin-angiotensin system
T2 - Inequality between the sexes in response to RAS stimulation and inhibition
AU - Sullivan, Jennifer C
PY - 2008/4/1
Y1 - 2008/4/1
N2 - The purpose of this review is to examine sex differences in response to stimulation and inhibition of the renin-angiotensin system (RAS). The RAS plays a prominent role in the development of chronic renal disease, and there are known sex differences not only in the expression level of components of the RAS but also in how males and females respond to perturbations of the RAS. In men, renal injury increases in parallel with increased activation of the RAS, while in women, increases in ANG II do not necessarily translate into increases in renal injury. Moreover, both epidemiological and experimental studies have noted sex differences in the therapeutic benefits following angiotensin-converting enzyme inhibitor and angiotensin receptor blocker treatment. Despite these differences, RAS inhibitors are the most commonly prescribed drugs for the treatment of chronic renal disease, irrespective of sex. This review will examine how males and females respond to stimulation and inhibition of the RAS, with a focus on renal disease.
AB - The purpose of this review is to examine sex differences in response to stimulation and inhibition of the renin-angiotensin system (RAS). The RAS plays a prominent role in the development of chronic renal disease, and there are known sex differences not only in the expression level of components of the RAS but also in how males and females respond to perturbations of the RAS. In men, renal injury increases in parallel with increased activation of the RAS, while in women, increases in ANG II do not necessarily translate into increases in renal injury. Moreover, both epidemiological and experimental studies have noted sex differences in the therapeutic benefits following angiotensin-converting enzyme inhibitor and angiotensin receptor blocker treatment. Despite these differences, RAS inhibitors are the most commonly prescribed drugs for the treatment of chronic renal disease, irrespective of sex. This review will examine how males and females respond to stimulation and inhibition of the RAS, with a focus on renal disease.
KW - Angiotensin receptor blocker
KW - Angiotensin-converting enzyme inhibitors
KW - Janus kinase/signal transducers and activators of transcription
KW - Nuclear factor-κβ
KW - Transforming growth factor-β
UR - http://www.scopus.com/inward/record.url?scp=41749092325&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=41749092325&partnerID=8YFLogxK
U2 - 10.1152/ajpregu.00864.2007
DO - 10.1152/ajpregu.00864.2007
M3 - Review article
C2 - 18287217
AN - SCOPUS:41749092325
VL - 294
JO - American Journal of Physiology - Heart and Circulatory Physiology
JF - American Journal of Physiology - Heart and Circulatory Physiology
SN - 0363-6135
IS - 4
ER -